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A B S T R A C T
The dried blood spot (DBS) method, which is a simple technique for blood sample processing involving the
placement of a drop of whole blood onto ﬁlter paper, has been used recently in clinical pharmacology to de-
termine blood concentrations of various drugs. This study examined the feasibility of the clinical application
of the DBSmethod for individual busulfan dose adjustments. Pharmacokinetic (PK) parameters of blood samples
for busulfan measurements determined using the DBS method were compared with those using plasma sep-
aration (the conventional method). Blood samples were collected from patients receiving i.v. busulfan as a
conditioning regimen before allogeneic hematopoietic stem cell transplantation at Toranomon Hospital, Japan.
Samples collected 2, 4, and 6 hours after the start of the ﬁrst drip infusion were processed by DBS or the con-
ventional method. The area under the blood concentration-time curve (AUC) and other PK parameters were
calculated to compare the 2 methods. Divergence of <20% in each parameter was considered acceptable. The
divergence range for each parameter was as follows: blood concentration at 2 hours after the start of drip
infusion, .6 to 8.2%; at 4 hours, .3 to 10.0%; at 6 hours, .3 to 14.2%; and AUC0–∞, .0 to 10.3%. None of the PK
parameters showed a divergence between the DBS method and the conventional method exceeding 20%, sug-
gesting that both methods are well correlated. The clinical application of blood sample processing with the
DBS method in the measurement of blood busulfan concentration may therefore be feasible, but further studies
are needed to conﬁrm these ﬁndings.
© 2016 American Society for Blood and Marrow Transplantation. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
INTRODUCTION
The dried blood spot (DBS)method is an approach to blood
sample processing whereby a drop of blood is placed onto a
designated ﬁlter paper (DBS card) from which target com-
pounds are extracted for quantitative determination. The
advantages of this method are that it requires only a trace
amount of blood formeasurement and that no plasma or serum
separation is needed. In addition, the procedures before
measurement are simple, DBS cards can be handled as non-
infectious specimens because viruses and othermicroorganisms
are inactivated, and temperature control of the DBS cards is
easily achieved during storage and transport [1,2].
The i.v. antineoplastic agent busulfan is widely used in the
conditioning regimen for hematopoietic stem cell transplan-
tation (HSCT) [3-5]. Its therapeutic eﬃcacy and toxicity are
known to correlate with the area under the blood
concentration-time curve (AUC) or the mean blood concen-
tration at steady state [6]. In general, an AUC0–∞ of 900 to
1500 μmol·min/L after a single infusion of .8 mg/kg in a 16-
dose regimen is associated with favorable HSCT outcomes
[7,8]. However, at an AUC0–∞ of ≤900 μmol·min/L the inci-
dence of graft failure increases, whereas at ≥1550 μmol·min/L
there is an increased risk of treatment-related toxicity such
as hepatic veno-occlusive disease [9,10]. Interindividual vari-
ability in the pharmacokinetics (PK) of busulfan has also been
observed in patients given i.v. busulfan injection [11,12], and
interindividual variability in metabolic drug handling may
contribute to a suboptimal outcome.
Therefore, monitoring of blood busulfan concentration is
desirable for i.v. busulfan injection, and dose adjustment based
on PK analysis of busulfan is being introduced [13]. For this
purpose, blood busulfan concentrations are determined using
HPLC [14-16], liquid chromatography tandem-mass spec-
trometry (LC-MS/MS) [17,18], and gas chromatography-mass
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spectrometry (GC-MS/MS) [10,19]. However, because of the
complicated processing and operation of instruments along-
side high equipment costs associated with the above
techniques (HPLC, LC-MS/MS, and GC-MS/MS), simple and ac-
curate measurement systems have not yet been fully
established in clinical practice.
The DBS method has previously been reported to be a
useful approach for measuring blood busulfan concentra-
tions, with a trueness < 14%, precision < 10%, and recovery
of 100% [20], although this study only included 4 pediatric
patients and measured blood concentrations of busulfan but
did not examine AUC [20]. Additionally, the DBS method has
been reported to have particular problems such that quan-
tiﬁcation may be affected by the patient’s hematocrit [21],
but this has not been fully investigated.
This study aimed to examine the potential clinical appli-
cation of the DBS method for individual busulfan dose
adjustments. Busulfan PK parameters were compared between
samples processed using the DBS method and those pro-
cessed using the conventional, separated plasma method.
METHODS
Subjects
The study was conducted in patients receiving busulfan as a condition-
ing regimen before allogeneic HSCT at Toranomon Hospital, Japan. Patients
who received allogeneic HSCT from June 2014 to August 2014 were in-
cluded. Busulfan was administered as an i.v. infusion at a dose of .8 mg/kg
(of recipient weight) over 2 hours, 4 times a day.
Blood Sampling
Samples for measuring blood busulfan concentrations were collected at
2 hours (the peak concentration at completion of infusion), 4 hours, and
6 hours after the start of the ﬁrst drip infusion. At each time point, approx-
imately 5mL of whole bloodwas collected using blood collection tubes coated
with EDTA dipotassium salt dihydrate.
Blood Sample Processing
Blood samples from each patient were processed using DBS cards (the
DBS method) or the conventional method using the plasma separation tech-
nique (the conventional method). A small amount (approximately 20 μL) of
the whole blood sample was dropped directly onto the DBS card (Whatman
903 Protein Saver Card; GE Healthcare Bio-Sciences Corp., Pittsburgh, PA),
which was then dried and immediately stored at not more than −15°C. The
remaining sample was centrifuged at 1500 × g for 5 minutes, and the sepa-
rated plasma was immediately frozen and stored. The DBS cards were
transported to Toray Research Center, Inc. (Tokyo, Japan), and plasma samples
were transported to the Department of Clinical Pharmaceutics, Doshisha
Women’s College of Liberal Arts (DWCLA) Faculty of Pharmaceutical Sci-
ences (Kyoto, Japan) for analysis. Both the dry DBS cards and plasma samples
were transported in a frozen state.
Measurement of Blood Busulfan Concentration
For DBS analysis, discs (internal diameter, 3mm) were punched out from
each whole blood spot and .5 mL of busulfan-d8 solution was added as an
internal standard. After standing for 10 minutes, the analyte was extracted
via sonication and stirring. The extract was evaporated to dryness at 40°C,
and the residue was reconstituted in 10% methanol. The reconstituted so-
lution was centrifuged at 1000 × g for 1 minute, and then 2 μL of the sample
was injected into the LC-MS/MS. For LC-MS/MS analysis, the Nexera MP
system (Shimadzu Corporation, Kyoto, Japan) was used as the HPLC instru-
ment and the AB SCIEX Triple Quad 6500 (AB SCIEX, Framingham, MA) as
the MS/MS instrument. A Kinetex C18 column (50 × 2.1 mm, 2.6 μm;
Phenomenex, Torrance, CA) was used for analysis, with the column tem-
perature set at 40°C. The mobile phase consisted of Mobile Phase A
(10 mmol/L ammonium formate) and Mobile Phase B (methanol), and sep-
aration was performed by gradient elution at a ﬂow rate of .5 mL/min. The
gradient program was 5% B over .5 minutes, followed by a linear increase
to 90% B over 2.5 minutes, holding at 90% B for up to 3.5 minutes, and then
column equilibration to the initial condition of 5% B over 4.5 minutes. The
MS instrument was operated in positive ion electrospray ionization mode
with multiple reaction monitoring. The collision energy and other param-
eters for each compound were optimized by infusing the standard solutions.
The multiple reaction monitoring transition was m/z 264.0 → 150.7 for bu-
sulfan and m/z 272.0 → 159.1 for busulfan-d8. The electrospray ionization
needle received a high voltage of 5.5 kV. The ion source temperature was
set at 500°C, and the nebulizer gas was set at 50 psi, heater gas at 60 psi,
and curtain gas at 20 psi. The collision gas ﬂow was set to 6 arbitrary units,
and analysis was performed in 4.5 minutes per sample. The measured blood
concentration data were sent to DWCLA.
Plasma busulfan concentrations were measured by HPLC as reported by
Chow et al. [14] with some modiﬁcations: 20 μL of 50 μg/mL chlorﬂuazuron
was added to .2 mL of plasma sample as the internal standard, mixed, and
then deproteinized by adding .4 mL of acetonitrile. After centrifugation at
1500 × g for 5minutes, .2mL of 1.17mol/LN,N-sodium diethyldithiocarbamate
solution and 2 mL of ethylacetate were added to .4 mL of the supernatant,
and the mixture was shaken for 10 minutes for derivatization. After cen-
trifugation at 1500 × g for 5 minutes, the supernatant was collected and
evaporated to dryness at 60°C. The residue was reconstituted in a mixture
of .4 mL of methanol and .6 mL of water, and the reconstituted solution was
injected into a solid-phase extraction cartridge Oasis HLB (Waters, Elstree,
UK), and then serially conditioned with 1mL of methanol and 2mL of water.
After washing with 1.6mL of 50%methanol, the sample was eluted with 2mL
of methanol, and the eluate was evaporated to dryness at 65°C. The residue
was reconstituted in 200 μL of the mobile phase as described below, and
70 μL of the solution was injected into the HPLC system. The HPLC system
consisted of a solvent delivery unit LC-20AT and UV absorption detector SPD-
10AVP (Shimadzu Corporation). The analytical column was an Inertsil ODS-
3V column (4.6 × 250 mm, 5 μm; GL Sciences, Eindhoven, the Netherlands),
and the mobile phase was a mixture of acetonitrile, tetrahydrofuran, and
water (11:4:5, v/v/v). The ﬂow rate was 1.0 mL/min, and the detection wave-
length was 254 nm. The retention times of busulfan and internal standard
were 11.0 and 13.2 minutes, respectively. The lower limit of quantitation of
busulfan by this method was 10 ng/mL, and intra- and interday variabili-
ties were within 5.0%.
Methods of Analysis and Evaluation
PK parameters AUC0–∞, clearance, volume of distribution, and elimina-
tion half-life were calculated from the blood concentration data obtained
with the 2 methods by applying the 1-compartment model, using the PK
analysis software Phoenix WinNonlin 6.4 (Pharsight Corp., Mountain View,
CA). The DBS method and conventional method were compared in terms
of AUC0–∞ and other PK parameters and evaluated based on the cross-
validation speciﬁed in the Guideline on Bioanalytical Method Validation in
Pharmaceutical Development [22]. Divergence of <20% in each parameter
was considered acceptable. The divergence was calculated by Formula 1 as
follows:
Divergence
DBS method Conventional method
Mean value of 
%( ) = −
DBS method
and conventional method
×100 (1)
In addition, the correlations in blood busulfan concentration and AUC0–∞
between the DBS method and conventional method were evaluated.
One issue of concern when using the DBS method is the effect of the
hematocrit [21], whereby the higher the hematocrit value, the higher the
blood viscosity. With the DBS method, in which whole blood is directly
applied to the card, a high hematocrit tends to result in falsely high drug
concentrations. Therefore, we also investigated the effect of the hemato-
crit on the measurement of blood busulfan concentrations in this study.
Ethical Considerations
This study was approved by the Independent Ethics Committee of
Toranomon Hospital and was conducted in line with the Declaration of Hel-
sinki. Written informed consent for participation in the study was obtained
from all patients. This study was conducted by sharing responsibilities among
the Department of Hematology of ToranomonHospital, Toray Research Center,
Inc., Otsuka Pharmaceutical Co., Ltd., and the DWCLA according to a con-
tract. DBS cards were transported to Toray Research Center, whereas plasma
samples were sent to DWCLA with anonymized and encrypted patient data.
Statistical Analysis
Regression analysis was used to assess the divergence between the 2
methods of the following values: (1) busulfan concentration, (2) busulfan
AUC0–∞, and (3) hematocrit and its effect on the measurement of blood bu-
sulfan concentrations. SPSS Statistics for Windows, version 23.0 (IBM Corp.,
Armonk, NY) was used for analysis.
RESULTS
The study included 10 patients (3 women and 7men). The
ages of patients ranged from 36 to 66 years (median, 56 years),
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and body weight ranged from 37.7 to 74.5 kg (median,
58.5 kg). Further details of patient characteristics are shown
in Table 1.
The values of PK parameters obtained by the convention-
al method and DBSmethod, as well as the divergence in these
values between the 2 methods, are shown in Table 2. The di-
vergence for each parameter ranged from .0% to 14.2% and
did not exceed 20%, which is the acceptance criterion de-
scribed in the Guideline on Bioanalytical Method Validation
in Pharmaceutical Development [22]. Figure 1 shows signif-
icant correlations in both the blood busulfan concentration
and AUC0–∞ between the conventional method and DBS
method (P < .01).
The relationship between the hematocrit value and the di-
vergence in blood busulfan concentration between the 2
methods is shown in Figure 2. No signiﬁcant correlation was
found between hematocrit value and divergence in blood bu-
sulfan concentration between the 2methods (P = .52). It appears
that the divergence value of the patient with the highest he-
matocrit value showed large deviation from the others. In this
patient, the largest deviation (divergence, −14.2%) was ob-
served 6 hours after initiation of infusion. Because this time
point also indicated the lowest blood busulfan concentration
among the three time points (C2, C4, C6), it tended to have a
larger deviation. Therefore, the deviation observed in this
patient was not particularly larger than that of the other pa-
tients. In fact, the deviation observed in the patient at 2 hours
after initiation of infusion was small (−.6%).
DISCUSSION
The DBS method has been reported to have several ad-
vantages over the conventional method of using separated
plasma samples, including being more straightforward, re-
quiring only a small amount of blood, and reducing the risk
of infection for healthcare and laboratory personnel [1,2]. Dose
adjustments are based on AUC, and to calculate AUC values
precisely, blood samples must be collected at several time
points, each requiring 200 μL of blood for analysis. The DBS
method requires only one-tenth of this amount (10 to 20 μL).
Furthermore, considering that not many institutions are
equipped with costly instruments such as HPLC, LC-MS/MS,
and GC-MS/MS, the DBS method may also offer an advan-
tage in terms of low cost and easy transportation of samples
to facilities equipped for analysis.
In this study, none of the PK parameters showed a diver-
gence > 20% between the DBS method and conventional
method, suggesting that bothmethodsmay bewell correlated.
Table 1
Patient Characteristics
Patient
No.
Sex Age
(yr)
Diseases Body Weight
(kg)
Dose
(mg)
Hematocrit
(%)
1 M 45 MDS 68.8 54 32.3
2 M 46 MDS 74.5 60 20.7
3 M 61 ALL 62.7 50 27.9
4 F 36 ALL 42.6 33 25.1
5 M 46 AML 60.2 48 27.1
6 M 60 ENKTL 56.7 45 32.0
7 F 66 ALL 37.7 33 18.2
8 M 55 ENKTL 56.1 45 34.1
9 F 62 PCL 40.4 32 25.0
10 M 56 PTCL-NOS 64.5 51 27.8
MDS indicates myelodysplastic syndrome; ALL, acute lymphoblastic leuke-
mia; AML, acute myeloid leukemia; ENKTL, extranodal natural killer/T cell
lymphoma; PCL, plasma cell leukemia; PTCL-NOS, peripheral T cell lym-
phoma not otherwise speciﬁed.
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In fact, the study demonstrated a signiﬁcant correlation
between the conventional and DBS methods over the entire
range of blood concentrations analyzed as well as for AUC0–∞.
Because this study was conducted to compare PK param-
eters determined by the DBS method and the conventional
method and because doses were not adjusted, blood sam-
plingwas performed at 3 time points, theminimumnecessary
number of points. Speciﬁcally, the 3 time points were se-
lected to verify that there are no differences in the determined
PK parameters from low to high blood concentrations between
the DBS method and the conventional method. The time
points selected were a point showing the highest concen-
tration (2 hours after the start of infusion), a point showing
the lowest concentration (immediately before the next in-
fusion, ie, 6 hours after the start of infusion), and a point
showing an intermediate concentration (4 hours after the start
of infusion). More time points would be required for calcu-
lating the AUC for dose adjustment. However, because PK
parameters determined at any time point from the lowest to
highest blood concentrations did not differ between the DBS
Figure 1. Correlation between the DBS method and conventional method for busulfan (A) concentration and (B) AUC0–∞. Blood samples for analysis were
collected at 2, 4, and 6 hours after the start of infusion. Correlation coeﬃcients for A and B were R2 = .9837 (y = .9903x, P < .01) and R2 = .8725 (y = 0.9986x,
P < .01), respectively. Sampling was from 10 patients.
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method and the conventional method, adding more blood
sampling time points is unlikely to reveal any signiﬁcant dif-
ference between these 2 methods. Thus, the clinical
application of the DBS method is not considered to pose any
problem. This indicates that the DBS method may be as ef-
fective as the conventional plasma separation method for
measuring blood busulfan concentrations and making indi-
vidual dose adjustments. Because the DBS method requires
only a small blood sample and also enables easy handling and
transportation, it may be particularly useful for centers using
an external institution for measurement of blood busulfan
concentration or, for example, in pediatric cases where col-
lecting a suﬃcient blood sample may be diﬃcult.
On the other hand, a particular issue of concern with the
DBS method is the apparent variability in blood concentra-
tion because of the effect of the hematocrit. The hematocrit
affects blood viscosity, with whole blood viscosity being in-
creased at higher hematocrit values. It has been reported that
because the rate of development of the sample applied to DBS
cards depends on viscosity, the drug concentration per unit
area of whole blood samples tends to increase compared with
plasma and urine samples [21]. In this study, the relation-
ship between the hematocrit value and divergence in the
blood busulfan concentration between the 2methods was in-
vestigated, but no correlation was found, suggesting that the
measurement of busulfan concentration using the DBS
method is not affected by the hematocrit. Because of im-
paired hematopoiesis, which is characteristic of patients
undergoing stem cell transplantation, the highest hematocrit
values found in this series of patients (34.1% in a man, 25.1%
in a woman) were still below general reference values; there-
fore, the effect of the hematocrit may not be as obvious.
In conclusion, the ﬁndings of this study demonstrate that
the clinical application of blood sample pretreatment using
the DBSmethod tomeasure blood busulfan concentrationmay
be feasible. Studies in larger groups of patients are recom-
mended to further explore these results.
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